Which should you choose? Here's what you need to know.
Cagrilintide works through the amylin system (appetite and satiety), while tirzepatide is a dual GIP/GLP-1 agonist. Tirzepatide is FDA-approved; cagrilintide is still in trials but shows strong results — especially combined with semaglutide as CagriSema.
On 9 Oct 2026 Peptide Compare tracked 38 vendors selling Cagrilintide, cheapest in stock $4.50 per mg at Amino Sequence, and 30 selling Tirzepatide, cheapest $1.76 per mg at Modern Research.
Cagrilintide is a long-acting amylin receptor agonist that mimics the satiety hormone amylin. It's being studied for weight management and is the amylin half of Novo Nordisk's CagriSema combination, which showed over 20% weight loss in the REDEFINE 1 trial. On its own, cagrilintide has a notably lower rate of nausea than most GLP-1-based options.
Choose Cagrilintide if:
You're interested in a different mechanism than GLP-1 agonists, want to avoid severe nausea, or are looking at next-generation combination approaches like CagriSema.
Tirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist that's already FDA-approved for both type 2 diabetes and weight management. Clinical trials demonstrated up to 22.5% body weight reduction, making it one of the most effective single-agent weight loss peptides available today.
Choose Tirzepatide if:
You want an FDA-approved, clinically proven option with extensive real-world data and strong weight loss results right now.
Once you've decided which peptide fits your needs, here's how they compare on price and vendor options. Prices verified Oct 9, 2026.
Our top-rated vendor for each, based on trust scores, purity testing, and price.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
We re-check vendor prices continuously and score vendors on Finnrick blind-test results — samples bought anonymously and sent to a lab, not vendor claims. No vendor can pay to rank higher. See our full methodology.